Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to ...

Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Merck recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining by 3.3%.

At the 2025 American College of Cardiology (ACC) meeting in Chicago, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial hypertension (PAH).